TGA approved new indication for semaglutide drug in December 2024, but allocation to PBS still to be decided
Get our breaking news email, free app or daily news podcast
A weight loss drug has been approved to treat heart disease in overweight and obese patients by Australia’s medicines regulator, in what experts say is a “new frontier for the drugs”.
The Therapeutic Goods Administration (TGA) granted approval in December 2024 for semaglutide 2.4 mg, sold under the brand name Wegovy, to be used as a complementary therapy for adults with both cardiovascular disease and high body mass index, to reduce the related risk of heart attack, stroke or death.
Sign up for Guardian Australia’s breaking news email
About Author
More Stories
Europe’s big carnivores are on the rise – but can we live with bears next door?
Nigeria sues crypto giant Binance for $81.5bn in economic losses and back tax
German voters head to polls facing world of change as far right waits in the wings